The First Affiliated Hospital, 71069Zhejiang University School of Medicine, Hangzhou, P.R. China.
IBM Dalian Global Delivery Company Limited, Shanghai, P.R. China.
Int J Biol Markers. 2022 Dec;37(4):404-411. doi: 10.1177/03936155221101206. Epub 2022 May 30.
Clusterin (CLU) is a pleiotropic protein with numerous functions. It has recently attracted considerable attention owing to its association with cancer progression and metastasis. However, its role in hepatocellular carcinoma (HCC) has not been investigated. This meta-analysis is the first evaluation of the diagnostic performance of CLU in HCC.
Articles published in PubMed, EMBASE, Web of Science, Wanfang Data Knowledge Service Platform, and China Science and Technology Journal Database until January 2022 were searched. Studies that reported the usefulness of CLU for the differentiation of HCC and non-HCC (e.g., liver cirrhosis, chronic hepatitis, and other benign liver disease) patients were selected. Alpha-fetoprotein (AFP) was used as a positive control in this study. The sensitivity, specificity, diagnostic odds ratio (DOR), and area under the curve (AUC) were compared between CLU and AFP.
Eight articles including 811 participants were included. The pooled sensitivity (95% confidence interval (CI)), specificity (95% CI), DOR (95% CI), and AUC (95% CI) were: 0.86 (0.78-0.91), 0.85 (0.75-0.91), 35 (13-94), and 0.92 (0.89-0.94) for CLU; 0.74 (0.67-0.81), 0.89 (0.79-0.94), 22 (8-61), and 0.87 (0.84-0.90) for AFP; 0.93 (0.88-0.96), 0.85 (0.68-0.94), 75 (21-262), and 0.95 (0.92-0.96) for CLU + AFP, respectively. Compared with AFP, CLU showed higher sensitivity, DOR, and AUC, as well as similar specificity. The combination of CLU and AFP resulted in higher sensitivity, DOR, and AUC.
Serum CLU is a better biomarker versus AFP for the diagnosis of HCC. The combination of CLU and AFP improved diagnostic performance.
簇集蛋白 (CLU) 是一种具有多种功能的多功能蛋白。由于其与癌症进展和转移的关联，最近引起了相当大的关注。然而，它在肝细胞癌 (HCC) 中的作用尚未得到研究。这项荟萃分析是首次评估 CLU 在 HCC 中的诊断性能。
检索了 2022 年 1 月之前在 PubMed、EMBASE、Web of Science、万方数据知识服务平台和中国科技期刊数据库上发表的文章。选择了报道 CLU 对 HCC 和非 HCC（如肝硬化、慢性肝炎和其他良性肝病）患者进行区分的有用性的研究。本研究中使用甲胎蛋白 (AFP) 作为阳性对照。比较了 CLU 和 AFP 的灵敏度、特异性、诊断比值比 (DOR) 和曲线下面积 (AUC)。
纳入了 8 篇包含 811 名参与者的文章。CLU 的合并敏感性（95%置信区间 (CI)）、特异性（95%CI）、DOR（95%CI）和 AUC（95%CI）为：0.86（0.78-0.91）、0.85（0.75-0.91）、35（13-94）和 0.92（0.89-0.94）；0.74（0.67-0.81）、0.89（0.79-0.94）、22（8-61）和 0.87（0.84-0.90）；0.93（0.88-0.96）、0.85（0.68-0.94）、75（21-262）和 0.95（0.92-0.96）。与 AFP 相比，CLU 显示出更高的灵敏度、DOR 和 AUC，以及相似的特异性。CLU 和 AFP 的联合使用可提高诊断性能。
血清 CLU 是诊断 HCC 的一种比 AFP 更好的生物标志物。CLU 和 AFP 的联合使用提高了诊断性能。
